Enbrel

The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI ® , an etanercept biosimilar referencing Enbrel ®. BENEPALI has been granted marketing authorization in the European Union (EU) for the treatment of adults with mo more

New data from the COMET trial, published in Arthritis & Rheumatism, demonstrate that combination therapy with etanercept and methotrexate over two years achieved radiographic remission in 90 per cent of evaluable subjects with early active rheumatoid arthritis (RA). The results also showed that the more

According to Frost & Sullivan, the pharmaceutical industry had witnessed a huge wave of mergers and acquisitions’ activities in the past decade. Recently, there has been a surge in M&A activities, especially mega-M&As. Clearly, the current economic downturn, compounded by the credit crunch, has had more

Summary Aims(s) SB4 has been developed as a biosimilar of etanercept. The primary objective was to demonstrate the PK equivalence between SB4 and EU sourced etanercept (EU‐ETN), between SB4 and US sourced etanercept (US‐ETN), and between EU‐ETN and US‐ETN. The safety and immunogenicity were al more

Summary Immunoadhesins are recombinant proteins that combine the ligand‐binding region of a receptor or adhesion molecule with immunoglobulin constant domains. All FDA‐approved immunoadhesins are designed to modulate the interaction of a human receptor with its normal ligand, such as Etanercept more

The Fc fusion technology has been introduced to generate long-acting antagonistic drugs such as Enbrel, Orencia and Amevive. Here, Genexine created a novel noncytolytic hybrid Fc (hyFc) as a carrier of agonistic protein drugs using naturally existing IgD and IgG4 Fcs without any mutation in the hyFc more